Clinical Trials Browser

Active not recruiting × durvalumab × Breast × Clear all

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT02484404 2026-03-25

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Phase 1/2 Active not recruiting

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Phase 3 Active not recruiting

Breast Neoplasms

NCT04176848 2026-02-18

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Phase 2 Active not recruiting

15 enrolled 7 charts

Breast Neoplasms

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04521686 2025-06-27

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT05498155 2025-06-10

OlympiaN

Phase 2 Active not recruiting

Breast Neoplasms

NCT03594396 2025-04-17

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04053322 2025-03-12

DOLAF

Phase 2 Active not recruiting

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer

NCT03820141 2025-03-10

DTP

Phase 2 Active not recruiting

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT03875573 2024-12-20

Neo-CheckRay

Phase 2 Active not recruiting

Breast Neoplasms

NCT03616886 2024-12-19

SYNERGY

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms